A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

PurposeThis study was conducted to evaluate the efficacy and safety of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC).Patients and methodsEligibility included histologic or cytologic diagnosis of SCLC, ECOG PS of 0–2, cancer progression following one or two prior chemotherapy or chemo-radiotherapy (CRT) and adequate organ functions. Treatment regimen consisted of a 6-week cycle of sunitinib given as 50 mg p.o. daily for 4 weeks followed by 2 weeks off. The primary end point was objective response rate (ORR).ResultsFrom March 2008 to October 2010, 25 patients were enrolled and 24 received treatment. The median age was 64.5 years; 22 patients (92%) were male. Eight patients (33%) displayed sensitive relapse. Seven patients (29%) received CRT and fifteen patients (63%) had received one prior chemotherapy. A median of 1 cycle (range 1–4) of sunitinib was administered, and 23 patients were evaluable for response. Two patients displayed partial response, and seven patients presented stable disease with a ORR of 9% (95% CI, 1–28%). The median progression-free (PFS) and overall survivals were 1.4 months (95% CI, 1.1–1.7) and 5.6 months (95% CI, 3.5–7.7), respectively. The common grade 3 or 4 toxicities included thrombocytopenia (63%), asthenia (29%) and neutropenia (25%).ConclusionsAlthough tumor response was noted in 2 patients, the median PFS was short and most patients were unable to tolerate the treatment. At the current dose schedule, sunitinib does not appear to warrant further evaluation.